KIMBERLY KAVULLA: Open Payments
NPI 1558904862 · RAVENNA, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 51 payments from 11 companies in 2025. Trend: 2023 $972 · 2024 $1,449 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $406 |
| Ardelyx, Inc. | 8 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| QOL Medical, LLC | 2 | $53 |
| Janssen Biotech, Inc. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
Products named: IBSRELA, RINVOQ, LINZESS, ENTYVIO, SKYRIZI, MAVYRET, Sucraid, TREMFYA.
Industry payments across OH — which companies pay providers there.
